It has been revealed that various therapeutic agents for lifestyle-related diseases could affect bone metabolism. For example, thiazolidines, loop diuretics and warfarin would be possibly disadvantageous to bone metabolism. In many cases with lifestyle-related disease, it is necessary to take the medicine over a long term. Therefore, we should pay enough attention to bone metabolism during the selection of medicine, especially in the treatment of a high risk group for bone fracture. However, a majority of these drugs lack the evidence with randomized controlled trials for osteoporotic fracture. Further clinical research should be required to clarify the impact of each drug on osteoporosis with lifestyle-related diseases.
|出版ステータス||Published - 01-11-2014|
All Science Journal Classification (ASJC) codes